ERBB2 and breast cancer: Similarly, increased tumor-stromal content in patients with HER2-positive breast cancer resulted in a markedly shorter DFS than lower tumor-stromal content (HR = 2.12, 95% CI = 1.26–3.58, P = 0.005; Fig. 3B).